Incisional Negative Pressure Wound Therapy for Prevention of Surgical Site Infection: A Systematic Review and Meta-Analysis.

Authors

Shaan Patel, Shiva A Nischal, Kush M Kale, Akash Dubb, Srinivas K Prasad, Daniel Refai

Published in

JAMA surgery. Aug 19, 2026. Epub Aug 19, 2026.

Abstract

Incisional negative pressure wound therapy (iNPWT) has been proposed as a nonantibiotic adjunct to standard dressings for preventing surgical site infection (SSI), but uncertainty remains regarding consistency across SSI subtypes and dressing-related harms.
To evaluate the efficacy and safety of iNPWT vs standard dressing in adults undergoing surgery.
PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception through March 7, 2026.
Randomized clinical trials (RCTs) enrolling adults in whom iNPWT was applied to primarily closed surgical incisions and compared with standard dressing.
Two reviewers independently extracted data. Risk ratios (RRs) and mean differences with 95% CIs were pooled using random-effects models.
The primary outcome was overall SSI. Secondary outcomes included SSI subtypes, wound dehiscence, seroma, skin necrosis, reoperation, readmission, mortality, skin blistering, and device-related adverse events.
Eighty-five RCTs comprising 16 980 patients (iNPWT, n = 8463; standard dressing, n = 8517) were included. The mean (SD) age was 48.3 (19.4) years (48.1 [19.5] years in the iNPWT group and 48.5 [19.4] years in the standard dressing group), and 5660 of 16 075 individuals (35.2%) were male (2889 [35.7%] in the iNPWT group and 2771 [34.7%] in the standard dressing group). iNPWT was associated with lower risk of overall SSI (RR, 0.64; 95% CI, 0.57-0.72), deep SSI (RR, 0.66; 95% CI, 0.51-0.86), superficial SSI (RR, 0.59; 95% CI, 0.49-0.72), wound dehiscence (RR, 0.73; 95% CI, 0.61-0.88), seroma (RR, 0.77; 95% CI, 0.63-0.94), reoperation (RR, 0.80; 95% CI, 0.64-0.99), and skin necrosis (RR, 0.38; 95% CI, 0.18-0.80). No significant differences were observed for organ-space SSI, readmission, or mortality. iNPWT was associated with higher risks of skin blistering (RR, 4.51; 95% CI, 2.37-8.58) and device-related adverse events (RR, 11.87; 95% CI, 4.74-29.74). The number needed to treat was 21 for SSI; the number needed to harm was 18 for skin blistering and 11 for device-related adverse events. Trial sequential analysis confirmed evidence for overall, deep, and superficial SSI. Certainty of evidence was moderate.
In this systematic review and meta-analysis of 85 RCTs, iNPWT was associated with lower risks of overall, deep, and superficial SSI and several wound complications but potentially higher risks of skin blistering and device-related adverse events. These findings support selective rather than routine use, particularly in patients at elevated risk of incisional wound complications.

PMID:
42616534
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.